Results 241 to 250 of about 54,581 (294)

Genotype-guided comparison of VEN/HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: a multicenter real-world study. [PDF]

Blood Cancer J
Chen X, Yan Y, Cheng Q, Tang Y, Xiao H, Li Y, Wang E, Zhang J, Wang L, Zhang Q, Li X.   +10 more
europepmc   +1 more source

An emerging triplet option for newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. [PDF]

Haematologica
Boussi L, Goldberg AD.
europepmc   +1 more source

Mismatch screening in Nicotiana benthamiana to explore Pik-1/Pik-2 paired NLR platforms for receptor engineering. [PDF]

New Phytol
Xi Y, Banfield MJ.
europepmc   +1 more source

Mitochondria of a human skeletal muscle cell line associate with the parasitophorous vacuoles of three archetypal lineages of <i>Toxoplasma gondii</i> and influence fatty acid import. [PDF]

FEMS Microbes
Christiansen C, Laue M, Blume M.
europepmc   +1 more source

A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns. [PDF]

Haematologica
Yousuf M, Faldu P, Abdelmagid M, Aperna F, Fathima S, Alsugair AKA, Csizmar CM, Lasho TL, Mangaonkar AA, Reichard KK, He R, Pardanani A, Gangat N, Patnaik MM, Tefferi A.   +14 more
europepmc   +1 more source

EMA/HMA - Publication of the Final Minutes of the HMA-EMA joint Big Data Steering Group teleconference

openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Environmental impact assessment of recycled HMA with RAP materials from the rotary decomposition process compared to virgin HMA and conventional recycled HMA

Journal of Cleaner Production, 2023
Xinman Ai, Zhongshi Pei, Junyan Yi
exaly   +2 more sources

Outcomes in AML patients receiving HMA + venetoclax combination with prior HMA exposure.

Journal of Clinical Oncology, 2021
e19011 Background: Venetoclax (Ven) is a BCL-2 inhibitor approved in combination with hypomethylating agents (HMAs) in newly diagnosed AML patients who are not candidates for intensive induction based on impressive response rates (CR+CRi of 66.4%) and median overall survival (14.7 months) compared to HMA therapy alone (DiNardo CD, NEJM, 2020).
Bakos Keegan Jonathan, Dena Blanding, Christopher Andrew Rangel, Sarah Pasyar, Elizabeth Goodwin Hill, James Davis, Irl Brian Greenwell, Praneeth Baratam, Brian T. Hess   +8 more
openaire   +1 more source

Novel therapies upon failure of HMA plus venetoclax

Hematology, 2023
Abstract The efficacy and tolerability of the combination of hypomethylating agents with venetoclax (HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice-changing milestone in the field. However, treatment failure and relapse remain major barriers to prolonged survival.
Onyee, Chan, Alison R, Walker
openaire   +2 more sources